Chandigarh, India, January 10, 2020 — MilliporeSigma, a leading science and technology company, today announced the opening of new, non-profit center where Indian students and researchers can learn the latest genome-editing and single-molecule biomolecule biomarker detection technologies from MilliporeSigma experts.
“With the rapidly growing biopharmaceutical industry in India and demand for therapies, researchers who collaborate with us will benefit from our expertise to enhance their scientific competency and develop advanced technologies to accelerate development and production of new therapies,” said Sunil Punjabi, country speaker and head of Research Solutions, Life Science, India. “They will gain hands-on experience and enhance their skills in areas such as cancer research and novel drug development, conducting real-time analysis on their samples as part of workshops here.”
The center was developed by MilliporeSigma in collaboration with CSIR-IMTECH, an institute of the Council of Scientific and Industrial Research, under the aegis of Ministry of Science and Technology. It focuses on research, development and training in new drug discovery, affordable healthcare, fast and accurate diagnostics as well as agriculture biotechnology. Located in Chandigarh, the center augments the Indian government’s initiative for life science skill building in the country.
Dr. Shekhar C. Mande, director general CSIR & Secretary DSIR, said this collaboration would be a new benchmark for up scaling employability skills for graduates and post graduates who are interested in life science careers.
“India is a country today with 65 percent of its youth in the working age group (15-59 years) and more than 54 percent of its total population below 25 years of age,” Dr. Mande said. “If ever there is a way to reap this demographic advantage, it has to be through skill development of the youth and I am happy that IMTECH has a role to play.”
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.